Experts unpack how frontline CD38 quadruplets reshape relapse strategy and high‑risk definitions, spotlighting talquetamab’s promise in myeloma.
Between the Lines: Interpreting Emerging Clinical Trial Data for Talquetamab in Relapsed/Refractory Multiple Myeloma Clinical Perspectives on MonumenTAL-3 and Emerging Bispecific Antibody Strategies
New trials show BCMA bispecifics and CAR‑T boost survival in early relapsed, high‑risk myeloma, outperforming Dara-based triplets.
Dr. Ajai Chari and Dr. Rahul Banerjee discuss the growing need for therapeutic targets beyond BCMA in relapsed/refractory multiple myeloma (RRMM) and examine the rationale for GPRC5D-directed therapies.
Dr. Ajai Chari and Dr. Rahul Banerjee review the clinical development of talquetamab in relapsed/refractory multiple myeloma (RRMM), focusing on key findings from the MonumenTAL-1 study and the evolution of GPRC5D-directed therapy.
Dr. Ajai Chari and Dr. Rahul Banerjee discuss the clinical rationale behind the phase 3 MonumenTAL-3 study and its role in confirming the benefit-risk profile of talquetamab in relapsed/refractory multiple myeloma (RRMM).
Dr. Ajai Chari and Dr. Rahul Banerjee review the key efficacy and safety findings from the phase 3 MonumenTAL-3 study in relapsed/refractory multiple myeloma (RRMM).
Dr. Ajai Chari and Dr. Rahul Banerjee discuss the evolving understanding of neurologic adverse events associated with GPRC5D-directed therapies in relapsed/refractory multiple myeloma (RRMM).
Dr. Ajai Chari and Dr. Rahul Banerjee explore future directions for talquetamab in relapsed/refractory multiple myeloma (RRMM), focusing on emerging combination strategies designed to enhance the activity of T-cell–redirecting therapies.
EP. 9: Relapsed/Refractory Multiple Myeloma: Sequencing CAR T-Cell Therapy and Bispecific Antibodies
Dr. Ajai Chari and Dr. Rahul Banerjee discuss the increasingly complex treatment sequencing decisions facing clinicians in relapsed/refractory multiple myeloma (RRMM) as the number of highly active immunotherapy options continues to expand.
Dr. Ajai Chari and Dr. Rahul Banerjee conclude the discussion by exploring future opportunities to further improve outcomes for patients with relapsed/refractory multiple myeloma (RRMM).
Advertisement
Advertisement
Trending on CancerNetwork
1
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
2
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
3
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
4
Defining the Objectives of an Analysis of Tarlatamab in Brain Metastases
5